London Jobs |
Manchester Jobs |
Liverpool Jobs |
Nottingham Jobs |
Birmingham Jobs |
Cambridge Jobs |
Glasgow Jobs |
Bristol Jobs |
Wales Jobs |
London Jobs |
Manchester Jobs |
Liverpool Jobs |
Nottingham Jobs |
Birmingham Jobs |
Cambridge Jobs |
Glasgow Jobs |
Bristol Jobs |
Wales Jobs |
Oil & Gas Jobs |
Banking Jobs |
Construction Jobs |
Top Management Jobs |
IT - Software Jobs |
Medical Healthcare Jobs |
Purchase / Logistics Jobs |
Sales |
Ajax Jobs |
Designing Jobs |
ASP .NET Jobs |
Java Jobs |
MySQL Jobs |
Sap hr Jobs |
Software Testing Jobs |
Html Jobs |
Job Location | Brentford |
Education | Not Mentioned |
Salary | Competitive salary |
Industry | Not Mentioned |
Functional Area | Not Mentioned |
Job Type | Permanent, full-time |
Site Name: UK - London - BrentfordPosted Date: Jul 9 2020Oncology Medical Director – Oncology (Grade 5) Company BackgroundGSK Oncology is one of GSK Pharma’s 4 core therapy areas and is considered a future growth driver for the company. In 2014, GSK divested its Oncology late stage development and commercial business (ie targeted therapies such as kinase inhibitors and other traditional anti-cancer agents) to Novartis. However, GSK retained its Oncology discovery/preclinical portfolio (comprised of innovative next generation anti-cancer agents) and infrastructure. Since 2014, GSK has progressed this innovative portfolio and has delivered over 16 novel assets into clinical development (alone or in partnership). Moreover, GSK Oncology has established a strong position and focus in four areas; namely, synthetic lethality, cancer epigenetics, immuno-oncology, and oncology cell therapies (TCR-T and CAR-T).The GSK Oncology vision is to maximise the survival of cancer patients by delivering transformational medicines alone or in combination. In addition to in-house discovery and development, the Therapy Area (TA) will rely on outside innovation to deliver this vision. Importantly, Oncology represents one of the most heavily invested and innovative therapy areas across the life sciences and Healthcare industry. The field is evolving at an unprecedented pace and, if leveraged/accessed properly via business development, is expected to contribute to the overall vision of GSK Oncology.DetailsAs a global healthcare company, GSK takes on some of the world’s biggest healthcare challenges. The biggest contribution we can make to society is to innovate and widen access to new medicines, vaccines and consumer healthcare products. We continue to be committed to develop medicines to support fighting cancer. Over the last few years our R&D team has been using ‘next generation’ technology platforms to increase understanding of disease mechanisms, which will help us deliver significant medical advances to cancer patients.Your role will be at the forefront of GSK’s re-emergence in discovering and providing cutting edge Immuno-Oncology treatments. Our leading Oncology asset is belantamab mafodotin, an anti B-cell maturation agent (BCMA) monoclonal immunoconjugate. This is a first in class antibody drug conjugate that has a four-fold mechanism of action with evidence of high efficacy in Multiple Myeloma patients. BCMA has been granted Breakthrough Therapy Designation from the FDA and EU Prime designation. Other assets such as ICOS for Head & Neck and Lung Cancer, NYESO-1 for synovial sarcoma and other solid tumours, M7824 (bintrafusp) for lunch and biliary tract cancers amongst others in our rich oncology pipeline.PRIMARY RESPONSIBILITIES: